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HypoxiaBackground and purpose: Patients with advanced NSCLC have survival rates <15%. The NOTCH pathway
plays an important role during lung development and physiology but is often deregulated in lung cancer,
making it a potential therapeutic target. We investigated NOTCH signaling in NSCLC and hypothesized
that high NOTCH activity contributes to radiation resistance.
Materials and methods: NOTCH signaling in NSCLC patient samples was investigated using quantitative
RT-PCR. H460 NSCLC cells with either high or blocked NOTCH activity were generated and their radiation
sensitivity monitored using clonogenic assays. In vivo, xenograft tumors were irradiated and response
assessed using growth delay. Microenvironmental parameters were analyzed by immunohistochemistry.
Results: Patients with high NOTCH activity in tumors showed significantly worse disease-free survival. In
vitro, NOTCH activity did not affect the proliferation or intrinsic radiosensitivity of NSCLC cells. In con-
trast, xenografts with blocked NOTCH activity grew slower than wild type tumors. Tumors with high
NOTCH activity grew significantly faster, were more hypoxic and showed a radioresistant phenotype.
Conclusions: We demonstrate an important role for NOTCH in tumor growth and correlate high NOTCH
activity with poor prognosis and radioresistance. Blocking NOTCH activity in NSCLC might be a promising
intervention to improve outcome after radiotherapy.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 440–445Lung cancer is the leading cause of cancer mortality worldwide
with overall 5-year survival rates <15%. Non small cell lung cancer
(NSCLC) is the most common type and found in 85% of cases. There
is an urgent need for novel approaches to combat NSCLC [1]. Tar-
geting the NOTCH signaling pathway is promising in this respect.
The NOTCH signaling pathway is a highly conserved pathway that
controls cell fate decisions in mammals [2]. NOTCH proteins are
cell surface transmembrane receptors that interact with adjacent
cells expressing membrane bound ligands. Ligand binding triggers
two consecutive proteolytic cleavages resulting in the release of
the cytosolic NOTCH intracellular domain (NICD) to the nucleus
where it activates gene transcription. Targets of canonical NOTCH
signaling include not only negative transcriptional regulators of
the HES and HEY-family, but also oncogenes such as Ras or Myc
[3]. In the developing lung, NOTCH signaling controls proximal–distal cell fates during branching morphogenesis and the pathway
is vital to maintain adult lung physiology [4]. Perturbations in the
NOTCH signaling pathway are frequent in NSCLC by deregulated
expression or via oncogenic mutation [5]. Activating mutations in
NOTCH1, similar to those found in T-ALL, occur in 10% of NSCLC
whereas in 30% of cases, loss of NUMB1, a negative regulator of
NOTCH, is observed [6]. In a large cohort of 355 NSCLC patients,
high NOTCH1 expression was a negative prognostic factor [7].
Aberrant NOTCH expression is also linked to pathways frequently
implicated in NSCLC, such as amplified EGFR [8] and mutant K-
Ras [9].
Standard of care for advanced NSCLC patients includes chemo-
radiotherapy. Unfortunately, resistance toward radiation often
contributes to therapy failure, an observation which in breast can-
cer [10] and glioblastoma [11] has been linked to a cancer stem cell
(CSC)/NOTCH phenotype. Little is known about the role of NOTCH
in radiation response for NSCLC. Given the (pre)clinical data that
implicate the NOTCH pathway in NSCLC and the observation that
resistance toward radiotherapy in various tumor types implicates
NOTCH signaling, we examined whether aberrant NOTCH signaling
J. Theys et al. / Radiotherapy and Oncology 108 (2013) 440–445 441contributes to diminished radiation response in NSCLC. Our find-
ings indicate that NOTCH promotes tumor growth and correlates
with a radioresistant phenotype in NSCLC in vivo and we propose
that targeting NOTCH in NSCLC patients may increase therapy re-
sponse and improve outcome.
Materials and methods
Patients
Patients who underwent a curative resection for stage I, II and
resectable stage IIIA, cN0-1 NSCLC at the Radboud University Nij-
megen Medical Centre between January 2002 and December
2008, of whom fresh frozen lung resection biopsies and/or pre-
treatment 18FDG-PET-scans were available, were included in this
study (n = 119) (for detailed patient characteristics see [12] and
Supplementary Table 1). Patients who received experimental
neo-adjuvant treatment were excluded (n = 5). Twenty seven fresh
frozen samples were not suitable for evaluation due to sampling
error (absence of tumor tissue, presence of inflammatory tissue
or necrosis) and two biopsies could not be retrieved. For treatment
outcome analysis, three patients with incomplete anatomical
resections based on unexpected stage IIIB/IV (TNM 7th edition)
were excluded.Cell lines and reagents
H460 (lung carcinoma) cells were grown in RPMI (PAA) supple-
mented with 10% FBS (PAA). H460 cells were transduced with viral
particles as described [13] by transfecting MIGR1-N1DEGFP
(NOTCHhi), MSCV-hMAML1(12-74)-GFP (NOTCHlo) or MIGR1 (con-
trol, MIGR1 is a MSCV derivative with IRES-GFP) (plasmids were
kind gift of J. Aster, Boston [14]). For NOTCH transcriptional assays,
a pGL4.24-12CSL luciferase reporter was transfected [15] to-
gether with pGL4.74 TK-hRL (Promega) for normalization. c-Secre-
tase inhibitor (GSI) dibenzazepine (DBZ) was used at a final
concentration of 200 nM or vehicle (DMSO) as a control. Dual lucif-
erase activity was measured on a Fluostar Omega plate reader
(BMG Labtech).Western blotting and real time quantitative PCR
SDS–PAGE, Western blot and qRT-PCR were performed accord-
ing to standard protocols [16]. Total RNA from cell lines and patient
samples was isolated using RNeasy (Qiagen) and Nucleospin RNAII
(BIOKE), respectively. Antibodies used are listed in Supplementary
Table 2. Primers used are listed in Supplementary Table 3.Proliferation assays and clonogenic survival analysis
For proliferation assays, cells were cultured in 24-well plates in
triplicate and phase contrast images were taken using the Incu-
Cyte™ at 4 h intervals for 4–5 days. Data were analyzed using Incu-
Cyte™ cell proliferation assay software. Clonogenic assays were
performed as described [17].In vivo xenograft studies
Animal experiments were in accordance with national guide-
lines. 3  106 NOTCHhi, NOTCHlo or control tumor cells were sub-
cutaneously injected in the flank of NMRI-nu mice. Animals were
randomly assigned to control or irradiation group. Tumor volumes
were measured 3/week in three orthogonal diameters. When tu-
mors reached 250 mm3, tumors were irradiated with a single
dose of 10 Gy (15 MeV e) using a linear accelerator (Varian). Re-
sponse was assessed by calculating the time for each tumor toreach 4 the treatment starting volume. The hypoxia marker
pimonidazole hydrochloride (60 mg/kg, i.p.) was injected 1 h be-
fore euthanizing the animals.Immunohistochemistry
Formalin-fixed, paraffin-embedded tumors were cut in 5 lm
sections and immunohistochemical stainings performed according
to standard protocol (Suppl. Table 2 for antibodies). Negative con-
trols were obtained by omitting the primary antibody. Quantifica-
tion of Ki67 was performed by determining the number of Ki67
positive nuclei as a proportion of total number of nuclei in 10 rep-
resentative fields of viable tumor tissue across multiple tumors per
group. Hypoxia was assessed in whole tumor sections with pimon-
idazole as a marker. Hypoxia and necrosis areas were quantified
using Leica Qwin morphometry software.Statistical analysis
Statistical analysis was carried out using GraphPad Prism (5.0b
for Mac OS). Log-Rank (Mantel Cox) or Mann–Whitney tests were
performed to determine statistical significance between groups.Results
High tumor NOTCH activity correlates with worse prognosis in
patients with NSCLC
To address if NOTCH activation is involved in NSCLC, we ana-
lyzed the expression profile of NOTCH receptors, ligands and target
genes in NSCLC patient samples. Our data show heterogeneous
expression of NOTCH pathway components across the samples
(Fig. 1A). To investigate the prognostic relevance of these findings,
we correlated the observed gene expression levels with patient
disease-free survival (DFS), calculated from the date of surgery to
the date of relapse. DFS was significantly worse in patients with
high tumor mRNA levels of NOTCH1 (p = 0.025), JAG2 (p = 0.025)
or HES1 (p = 0.013) (Suppl. Fig. 1). DFS of NSCLC patients whose tu-
mors exhibited high levels of all three was significantly worse than
other patients (p = 0.006) (Fig. 1B). These data indicate broad acti-
vation of the NOTCH pathway in human NSCLC with a worse out-
come in patients with the highest expression.NOTCH activity does not affect proliferation or radiation sensitivity
in vitro
To investigate the role of deregulated NOTCH signaling in
NSCLC, we transduced H460 cells to have constitutive high, normal
or low NOTCH activity, respectively. GFP+ cells were sorted by
FACS analysis (Suppl. Fig. 2) and lysates analyzed with cleavage
specific antibodies for activated NOTCH1 and GFP expression by
Western Blot (Fig. 2A). Differential NOTCH transcriptional activity
was confirmed using reporter assays (Fig. 2B) and target gene
expression analysis (Suppl. Fig. 3). Although blocking of NOTCH
activity has been shown to affect proliferation in certain tumors
[18], we found that increased or decreased NOTCH activity did
not significantly change in vitro proliferation rates (Fig. 2C). Since
we are specifically interested in the effect of aberrant NOTCH
expression in NSCLC in radiotherapy (RT) resistance, we examined
the response to ionizing radiation. Intriguingly, cells with hyperac-
tivated or attenuated NOTCH activity showed similar surviving
fractions as control cells (Fig. 2D) indicating that the NOTCH sig-
naling pathway does not affect the intrinsic radiosensitivity of
the cells.
Fig. 1. Expression of NOTCH pathway components is heterogeneous and indicative as prognostic indicator for NSCLC. (A) qRT-PCR analysis of Notch receptors, ligands and
target genes in 89 NSCLC tumors. Values are normalized to HPRT. (B) Kaplan–Meier curves showing DFS of the same patient population.
442 NOTCH and radioresistanceNOTCH activity enhances tumor growth and decreases radiation
sensitivity in vivo
Since the lack of a biological effect of NOTCH on proliferation or
radiation sensitivity in vitro could be caused by the absence of the
naïve tumor microenvironment, we next addressed the role for
NOTCH signaling in growth and response to radiotherapy of NSCLC
xenografts in vivo. Tumors were established from control, NOTCH1
and DNMAML1 overexpressing H460 cells and tumor growth rate
evaluated (Fig. 3A). NOTCH target gene expression in the tumors
mirrored observations from the H460_DNMAML and H460_N1DE
H460 cell lines (Suppl. Fig. 4A). N1DE-expressing tumors
(NOTCHhi) grew significantly faster (p < 0.05, average doubling
time 6.3 days) than the H460_ctrl tumors (average doubling time
8.5 days) whereas the doubling time of DN_MAML-expressing
NOTCHlo tumors was significantly higher (p < 0.05, average dou-
bling time 14.3 days) (Fig. 3B). This differential growth behavior
was also reflected in a significantly different Ki67 proliferation in-
dex across the groups (Fig. 3C). To investigate the effect of differen-tial NOTCH activity on the microenvironment, we quantified the
hypoxic and necrotic area fraction in entire tumor sections using
immunohistochemical analysis. A significantly higher hypoxic
fraction (p < 0.01) was found in NOTCHhi tumors compared to con-
trol and NOTCHlo tumors. Similar results were obtained when the
necrotic areas were excluded during the analysis (not shown).
NOTCHlo tumors were significantly more necrotic (p < 0.05)
(Fig. 3C). Overall, these data indicate the importance of the micro-
environment when assessing NOTCH-related effects and correlate
NOTCH activity with proliferation in vivo.
Because NOTCH activity correlates with worse outcome, we
investigated if high NOTCH activity negatively affected the re-
sponse to radiotherapy, part of standard care for NSCLC. Although
radiation caused a significant growth delay in both NOTCHwt and
NOTCHhi tumors (p < 0.05, compared to non-irradiated group),
NOTCHhi tumors were significantly more resistant than control tu-
mors (p = 0.01) (Fig. 3D). The average time to reach 4 the starting
volume following RT was 36.2 days for H460_ctrl and 16.9 days for
Fig. 2. NOTCH activity levels do not affect proliferation and radiosensitivity in vitro. (A) Western blot analysis of indicated H460 cells for active form of Notch1 (NICD) (upper
panel), GFP expression (26 kDa for wt protein and 36 kDa for fusion protein with Mam (12–74)) (middle panel) and actin (loading control, bottom panel). (B) NOTCH
transcriptional activity in H460_DNMAML or H460_N1DE cells compared to parental control cells. H460_ctrl and H460_DNMAML cells were co-cultured with Jagged1-
expressing cells to induce ligand-dependent Notch activation. (C) Proliferation curves of indicated cell lines. (D) Clonogenic survival curves following RT. Experiments were
done in triplicate. Shown are average ± SEM.
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quence of the increased proliferation in NOTCHhi tumors, as the
specific tumor growth delay (corrected for growth rate) was also
significantly different (p = 0.02). In the NOTCHhi tumors, the hyp-
oxic fraction further increased upon radiation (p < 0.05), a phe-
nomenon not observed in the irradiated H460_ctrl tumors. In
these latter tumors the hypoxic fraction remained unaltered upon
radiation, yet the necrotic fraction increased (p < 0.05) (Fig. 3F).Discussion
In the current study, we show that high tumor NOTCH activity
is associated with decreased overall survival in NSCLC patients. We
demonstrate that inhibition of the NOTCH cascade slows tumor
growth in vivo while ectopic activation enhances the growth rate.
High proliferation rate is a hallmark of cancer and meta-analysis in
lung cancer has reported high Ki67 to be an adverse prognostic
indicator [19]. Our observation that high NOTCH expression in-
duces resistance to radiotherapy is important, as radiotherapy is
standard of care for the majority of NSCLC [1]. Whereas we have
only addressed the effect of hyperactive NOTCH on a single radia-
tion dose, it will be important to investigate how ectopic NOTCH
signaling affects the response to clinically relevant fractionated
therapy as well. Intriguingly, neither proliferation nor response
to radiation was different when assessed in vitro. This indicates
that the outcome of aberrant NOTCH activity in solid tumors ishighly context-dependent and is determined by interactions with
the microenvironment.
As overall survival rates are very poor for NSCLC, improvement
of local tumor control is urgently needed. Our data propose that
patient stratification based on NOTCH tumor activity could be an
important first step toward selection of patients that may benefit
from the addition of NOTCH inhibition strategies. Our clinical data
are in line with previous observations showing that high NOTCH
activation in NSCLC results in worse prognosis [7]. Interestingly,
Donnem et al. showed the poorest survival for patients co-express-
ing high levels of NOTCH1 and VEGF-A. This mutual overexpres-
sion could well reflect a higher level of hypoxia in these
neoplasms, which is in agreement with our observations of a high-
er hypoxic fraction in NOTCHhi tumors. Since hypoxia leads to
treatment resistance, the increased hypoxic fraction in NOTCHhi
tumors is consistent with their radioresistant phenotype. Multiple
observations link hypoxia and NOTCH signaling. Hypoxia activates
Delta-NOTCH signaling in endothelial cells during tumor angiogen-
esis via VEGF [20]. Recently, Liu et al. showed that blocking NOTCH
signaling with anti-Dll4 mAb’s in head and neck or colon xeno-
grafts alone or in combination with RT delayed tumor growth by
promoting non-functional angiogenesis and extensive tumor
necrosis [21]. Although the exact mechanism(s) responsible for
the radioresistant phenotype here remain to be established, the
extensive necrosis we observed in tumors with blocked NOTCH
activation, points in the same direction. Our future studies will fur-
ther elaborate on the underlying mechanisms. In NSCLC, overex-
pression of NOTCH1 promotes survival under hypoxia [22]
Fig. 3. High NOTCH activity results in accelerated tumor growth and increased radioresistance in vivo. (A) Normalized xenograft volumes of NOTCHhi, NOTCHlo and NOTCHwt
tumors. Volumes were normalized to the start of measurements (day 0). (B) Tumor doubling times for individual tumors in the different groups. (C) Representative
immunohistochemistry sections of the indicated tumors at the endpoint stained for hypoxia (pimonidazole, 20 magnification, upper panel) and proliferation (Ki67, 5
magnification, lower panel). Necrotic areas (N) are outlined in the H/E stained sections (upper panel). Right panels show quantification of at least 6 different tumors (hypoxia/
necrosis) and 10 representative fields of viable tumor sections (Ki67)). Shown are average ± SEM. (D) Mean xenograft volumes of the indicated groups following RT (10 Gy) at
day 0. Volumes were normalized to the treatment start (day 0). (E) Kaplan–Meier curves showing times to reach the endpoint (4 tumor volume at start of RT) for H460_ctrl
and NOTCHhi ±RT. (F) Quantification of hypoxia (left) and necrosis (right) for the indicated groups. Error bars represent SEM. Asterisk indicates significance (⁄p < 0.05,
⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001), NS, not significant.
444 NOTCH and radioresistancewhereas hypoxia in turn, leads to upregulation of the NOTCH path-
way, inducing NOTCH dependent migration and invasion [23].
Interestingly, cancer stem cells (CSCs) have been shown to reside
in the hypoxic tumor microenvironment [24]. A significant correla-tion between the SC marker ALDH1A1 and poor prognosis was
found in a cohort of >200 NSCLC samples. The proportion of these
ALDH1A1+ cells was reduced upon NOTCH inhibition, showing
their NOTCH-dependency [25]. Also CD133+ cells isolated from pri-
J. Theys et al. / Radiotherapy and Oncology 108 (2013) 440–445 445mary NSCLC have tumor initiating capacity compared to CD133
and an active NOTCH cascade [26]. In both breast cancer [10]
and glioma [11], this CSC/NOTCH phenotype has been directly
linked to radiation resistance. Whether CSCs also contribute to
the decreased radiation response in NSCLC as in our study is cur-
rently under investigation. From a treatment point of view, it is
promising that synergism has also been shown between NOTCH
inhibition and commonly used chemotherapeutics in NSCLC
[26,27].
Overall, ample data suggest that NOTCH is an attractive target
for cancer treatment. Not surprisingly, there are currently over
50 registered phase I/II clinical trials using NOTCH inhibitors. We
demonstrate an important role for NOTCH in tumor growth and
correlate high NOTCH activity with poor prognosis and radioresis-
tance. Blocking high tumor NOTCH activity might thus be poten-
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